Venture capital-backed CoLucid is looking for drug development partners to help advance its proposed migraine treatment.

MedCity News, a content partner with WRAL Tech Wire, reports that CoLucid is “currently in talks with potential partners who could take its investigational migraine headache treatment into late-stage clinical trials.”

Triangle venture capital firm Pappas Ventures launched the company, which has raised some $40 million, in 2005.

For details, read here.

Get the latest news alerts: Follow WRAL Tech Wire at Twitter.